Welcome the Town of Clayton, North Carolina

Grifols Opens State-of-the-Art Facility in Clayton Like No Other in the World

06/17/2014

Conference room stage with two men in suits standing at the podium

Town of Clayton Mayor Jody McLeod helped play host to a crowd of international, national and state dignitaries Tuesday as Spanish pharmaceutical giant Grifols celebrated the grand opening of what will be the world's largest and most technically advanced plasma fractionation facilities. The plant on US 70 in Clayton will soon produce 6 million liters of life-saving plasma every year to help treat rare, chronic diseases such as neurological disorders, immune deficiencies, hemophilia and genetic emphysema.

"We are incredibly honored that Grifols chose to make a $370 million capital investment here in Clayton," said Mayor McLeod.  "They were already our largest private employer in Johnston County with more than 1,600 jobs.  Now this state-of-the-art facility will add 200 more.  The Town of Clayton looks forward to continuing our wonderful relationship with Grifols and are proud that we can now boast being home to one of the most innovative medical plants on the planet."

Media staff holding microphones near executive who is speaking.Grifols President and CEO Victor Grifols, and Greg Rich, CEO of Grifols Inc., accompanied Mayor McLeod and other Town of Clayton leaders on a tour of the new facility. They were joined by the President of the Government of Catalonia, Artur Mas; His Excellency Ramon Gil-Casares, Spanish Ambassador to the United States; and Sergi Mingote, Mayor of Parets del Vallès, Barcelona, where Grifols has one of its three manufacturing plants for plasma fractionation. 

North Carolina Governor Pat McCrory was on hand as well and touted the relationships established between the two countries and the company to expand pharmaceutical production.

Three Grifols executive standing at podium on stage clapping."The reliance on manufacturing here in North Carolina is very strong" he said. "We cannot live off the service sector alone."

The new 155,000 square-foot North Fractionation Facility (NFF) is one of the largest capital projects in Johnston County history and will contribute to Grifols retaining 2,300 jobs statewide. Grifols' North Fractionation Facility will be the world's largest and one of the most technologically advanced plasma fractionation facilities, almost doubling production capacity in Clayton from 3.2 million liters of plasma annually to 6 million liters in 2015.

Grifols also has a corporate office and manufacturing facilities in Los Angeles, CA, testing labs in San Marcos and Austin, TX and 150 plasma donation centers across the United States. Additionally, the company has manufacturing facilities in  San Francisco, CA producing antigens for immunological diagnostics, as well as the Grifols Academy of Plasmapheresis, a world-class education and training facility headquartered in Glendale, AZ. In total, Grifols employs over 9,600 people in the US, representing approximately 73% of its 13,200 employees worldwide.

Crowd seated in conference room listening to speaker."As a leading healthcare company, one of Grifols' main goals since being founded in the 1940's has been to advance the plasma industry. Today, I take great pride in our pioneering spirit that has allowed us to build the world's largest and one of the most innovative plants producing plasma medicines. The donors who make our life-saving therapies possible, along with all Grifols employees, share my passion for the patients that we continue to serve," said Victor Grifols, President and CEO of Grifols.

In addition, Mr. Grifols remarked that "choosing North Carolina for this facility is not a coincidence by any means. The US has always represented one of our most important markets, both past and present. Our investment of more than $7 billion since 2001 in this country demonstrates our long-term commitment to growth."

Grifols exterior facility.NFF was recently named the 2014 Facility of the Year for Project Execution by the International Society for Pharmaceutical Engineering (ISPE). The 155,000 square-foot facility features technologically advanced systems and processes to ensure the highest standards of product quality and high production capacity in plasma fractionation.

Fractionation is the first step in the production of plasma-derived therapies, which involves subjecting plasma to various changes of temperature and chemical conditions, causing each of the proteins with therapeutic properties to separate out. These proteins have to be purified and formulated before they can be used as medicines. The medicines manufactured by Grifols from plasma include immunoglobulin, for the treatment of primary immune deficiency and a neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP), factor VIII, for the treatment of hemophilia A, albumin, to re-establish and maintain blood volume and alpha-1 antitrypsin for the treatment of genetic emphysema.

Since 2001, the company has invested more than $7 billion in the US, including both capital expenditures (CAPEX) and strategic acquisitions that have resulted in the company accounting for approximately 20% of the global plasma therapies market, in addition to leading other complementary business areas, such as transfusion medicine.

Inside Grifols facility with production equipment.The $370 million invested in NFF at its Clayton facility is included in the Capital Investment Plan (CAPEX) for the period 2012-2014. In addition, organic growth continues and new investments are planned to expand and increase Grifols' production facilities in both Spain and the United States. In fact, Grifols plans to allocate approximately €600 million to capital expenditures between 2014 and 2016.

A substantial portion of the investment plan will go towards the expansion of the albumin purification plants in Los Angeles, CA and Clayton, NC, and also towards a new warehouse at Clayton's complex, while construction of the new alpha-1 antitrypsin purification area in the Parets del Vallès (Barcelona) complex is one of the much highlighted projects in Spain.

About Grifols

Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.

The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donor centers in the U.S., and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers, and is a recognized leader in transfusion medicine.

For more information on Grifols and its facilities, please visit www.grifols.com

back to list
Latest News
Video Gallery
© Town of Clayton All Rights Reserved